bioMérieux S.A (BIM) | Stock Overview & Key Data
bioMérieux S.A. | Large-cap | Healthcare
bioMérieux S.A. | Large-cap | Healthcare
bioMérieux S.A Performance Comparison
Stock Range
Today's Range
Low: €124.70
High: €126.40
on August 8, 2025
52 Week Range
Low: €95.35
High: €127.30
on August 8, 2024
on July 29, 2025
All-Time High: €144.80 on October 12, 2020
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€14.5B
EPS
3.64
P/E Ratio (TTM)
33.63
Forward P/E
26.78
P/B Ratio
3.43
PEG Ratio
26.78
Div. Yield
N/A
ROE
10.68%
Beta
0.452
Debt to Equity
11.65
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
16.82%
Profit Margin
10.86%
Returns and Earnings
Return on Assets (TTM)
7.23%
Return on Equity (TTM)
10.68%
EBITDA
€943.1M
Net Income (TTM)
€432.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€33.75
Quarterly Revenue Growth (YoY)
9.10%
Quarterly Earnings Growth (YoY)
10.70%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| bioMérieux S.A BIM | 14.53B Large-cap | -0.56% | 4.95% | 8.78% | 10.41% | 21.81% | 28.57% | 22.47% | -9.35% |
| Eurofins Scientific ERF | 11.98B Large-cap | -2.41% | 8.99% | 16.32% | 28.82% | 34.71% | 24.34% | -13.14% | 0.27% |
| Lumibird S.A LBIRD | 425.96M Mid-cap | 7.30% | 7.88% | 73.36% | 160.50% | 106.77% | 108.67% | -5.48% | 73.08% |
| Eurofins Cerep SAS ALECR | 88.77M Small-cap | -3.83% | 0.00% | -14.56% | -14.56% | -10.20% | -10.66% | -13.73% | 162.69% |
| Klea Holding ALKLH | 59.69M Small-cap | -5.00% | 5.56% | 5.56% | 0.00% | 11.76% | 11.76% | 0.00% | 0.00% |
| Predilife S.A ALPRE | 12.80M Small-cap | -2.87% | -8.40% | -7.40% | -11.05% | -5.06% | -28.69% | -44.59% | -54.32% |
Ownership & Short Interest
Insider Ownership
62.75%
Institutional Ownership
21.15%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
114K
Average 90-Day Volume
108K
bioMérieux S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in bioMérieux S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIM's 52-week high and low?
- In the last 52 weeks, bioMérieux S.A reached a high of €127.30 (on July 29, 2025) and a low of €95.35 (on August 8, 2024).
- What is the market cap and P/E ratio for BIM?
- Curious about bioMérieux S.A's size and valuation? Its market capitalization stands at 14.53B. When it comes to valuation, the P/E ratio (trailing twelve months) is 33.63, and the forward P/E (looking ahead) is 26.78.
- Does BIM pay dividends? If so, what's the yield?
- As for dividends, bioMérieux S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are bioMérieux S.A's main competitors or similar companies to consider before investing?
When looking at bioMérieux S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eurofins Scientific
ERF11.98B Healthcare Diagnostics & Research 24.34% -13.14% Lumibird S.A
LBIRD425.96M Healthcare Diagnostics & Research 108.67% -5.48% Eurofins Cerep SAS
ALECR88.77M Healthcare Diagnostics & Research -10.66% -13.73% Klea Holding
ALKLH59.69M Healthcare Diagnostics & Research 11.76% 0.00% Predilife S.A
ALPRE12.80M Healthcare Diagnostics & Research -28.69% -44.59% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for bioMérieux S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of bioMérieux S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.68%, the Debt to Equity ratio from the most recent quarter is 11.65, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BIM?
- Looking at bioMérieux S.A's growth, its revenue over the trailing twelve months (TTM) was €4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.10%, and quarterly earnings saw a YoY growth of 10.70%.
- How much of BIM stock is held by insiders and institutions?
- Wondering who owns bioMérieux S.A stock? Company insiders (like executives and directors) hold about 62.75% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 21.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.